Newland Pharmaceutical Co., Ltd., founded in 2005, is a publicly listed company (Stock: Xin Tiandi, 301277.SZ) focused on pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms (FDFs).

NewlandPharma is one of the world’s leading manufacturers of D(-)-p-Hydroxyphenylglycine (D-HPG) and p-Toluenesulfonic Acid (PTSA), contributed to the development of industry standards for four products, including D-HPG, D-HPG Methyl Ester, PTSA, and Glyoxylic Acid.

NewlandPharma holds 13 patents covering key production technologies, especially the D-HPG synthesis technology has been granted in eight countries, including the US, the UK, Japan, and India.

With two R&D centers in Beijing and Zhengzhou, NewlandPharma continues to attract top industry talent and introduce advanced technologies. Driven by innovation and a commitment to better health, NewlandPharma is advancing pharmaceutical solutions that make a lasting impact on lives around the world.